INS316 solution for inhalation + hypertonic saline 3% sodium chloride solution
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Interstitial Lung Disease
Conditions
Interstitial Lung Disease
Trial Timeline
Jan 1, 2003 → Apr 1, 2004
NCT ID
NCT01381666About INS316 solution for inhalation + hypertonic saline 3% sodium chloride solution
INS316 solution for inhalation + hypertonic saline 3% sodium chloride solution is a phase 2 stage product being developed by Merck for Interstitial Lung Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT01381666. Target conditions include Interstitial Lung Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01381666 | Phase 2 | Terminated |
Competing Products
20 competing products in Interstitial Lung Disease